Announcement of coverage for autologous blood-derived products for the treatment of chronic wounds

Medicare announced on August 2^nd the conditions under which Medicare will be provide coverage for autologous blood-derived products for the treatment of chronic wounds.

CMS issued the National Coverage Determination: Decision Memorandum for CAG-00190R3 – Autologous Blood-Derived Products for Chronic Non-Healing Wounds. Link provided below.

CMS will cover autologous platelet-rich plasma (PRP) only for patients who have chronic non-healing diabetic, pressure, and/or venous wounds and when all the following conditions are met:

The patient is enrolled in a clinical research study that addresses the specific questions using validated and reliable methods of evaluation.
Clinical study applications for coverage pursuant to this National Coverage Determination (NCD) must be received by August 2, 2014.
The clinical research study meets specific requirements identified in the Decision Memo.

Detailed information on Decision Memorandum for CAG-00190R3 is available here.

Disclaimer

While AAWC makes every effort to present accurate and reliable information on this website, AAWC does not endorse, approve, or certify such information, nor does it guarantee the accuracy, completeness, efficacy, timeliness, or correct sequencing of such information. Use of any information found on this website is voluntary. Reference on this website to any specific commercial product, process or service by trade name, trademark, service mark, manufacturer, and corporation or otherwise does not constitute or imply endorsement, recommendation, or favoring by AAWC.

AAWC (including its employees and agents) assumes no responsibility for consequences resulting from the use of the information found on this site (or from the use of the information obtained at linked internet addresses), or in any respect for the content of such information, including (but not limited to) errors or omissions, the accuracy or reasonableness of factual or scientific assumptions, studies or conclusions, the defamatory nature of statements, ownership of copyright or other intellectual property rights, and the violation of property, privacy, or personal rights of others. AAWC is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on such information.

Association for the Advancement of Wound Care - Professional Services

Announcement of coverage for autologous blood-derived products for the treatment of chronic wounds

Detailed information on Decision Memorandum for CAG-00190R3 is available here.